• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM
Click for more information
6.56% 28.5¢

IMMUTEP LIMITED - Announcements

Market Cap $486.6M  ! watchlist Created with Sketch. Add to my watchlist

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IMM Information Required Under Listing Rule 3.10.5A15/05/15
IMM Appendix 3B15/05/15
IMM Prima Biomed Announces A$15m Investment from RidgebackPRICE SENSITIVE14/05/15
IMM Prima announces Japanese CollaborationPRICE SENSITIVE11/05/15
IMM Prima to present at Canary Networks Investor Roadshow29/04/15
IMM Appendix 4C - quarterlyPRICE SENSITIVE16/04/15
IMM Half Yearly Report and AccountsPRICE SENSITIVE27/02/15
IMM Prima BioMed Prioritising IMP 321PRICE SENSITIVE27/02/15
IMM Detailed Investor Presentation27/02/15
IMM Introductory Investor Presentation27/02/15
IMM Appendix 4C - quarterlyPRICE SENSITIVE30/01/15
IMM Financial milestone payment to be received from GSKPRICE SENSITIVE27/01/15
IMM Cleansing Notice & Appendix 3B23/01/15
IMM R&D Tax Incentive Refund ReceivedPRICE SENSITIVE20/01/15
IMM Stuart Roberts appointed Global Head of Investor Relations20/01/15
IMM Change of Director's Interest Notice07/01/15
IMM Prima receives NASDAQ deficiency notice29/12/14
IMM Notice of Grant received from Canadian Patent OfficePRICE SENSITIVE22/12/14
IMM Prima completes acquisition of ImmutepPRICE SENSITIVE17/12/14
IMM Prima initiates Pancreatic Clinical Trial with CVacPRICE SENSITIVE15/12/14
IMM Appendix 3B12/12/14
IMM Cleansing Notice & Appendix 3B12/12/14
IMM Cleansing Notice & Appendix 3B11/12/14
IMM Enhancement of manufacturing and logistics capabilitiesPRICE SENSITIVE05/12/14
IMM Change of Director's Interest Notice28/11/14
IMM Appendix 3B28/11/14
IMM Results of Meeting14/11/14
IMM 2014 AGM Presentations14/11/14
IMM 2014 AGM Chairman's Address14/11/14
IMM Society for Immunotherapy of Cancer poster presentation10/11/14
IMM Cleansing Notice & Appendix 3B06/11/14
IMM CVac demonstrates overall survival benefitPRICE SENSITIVE06/11/14
IMM Supplemental Information for Shareholder Conference Call23/10/14
IMM Conference Call to discuss acquisition of Immutep21/10/14
IMM Appendix 4C - quarterlyPRICE SENSITIVE21/10/14
IMM Notice of Allowance for IMP321 PatentPRICE SENSITIVE14/10/14
IMM Prima Newsletter13/10/14
IMM Notice of Annual General Meeting/Proxy Form13/10/14
IMM Annual Report to Shareholders10/10/14
IMM Annual Report on Form 20-F filed with SEC10/10/14
IMM Cleansing Notice & Appendix 3B02/10/14
IMM Prima secures funding from US institutional investor02/10/14
IMM Proposed Acquisition of ImmutepPRICE SENSITIVE02/10/14
IMM Appendix 3B19/09/14
IMM Appendix 4E & 2014 Full Year Statutory AccountsPRICE SENSITIVE27/08/14
IMM Prima to present at Society for Immunotherapy of Cancer19/08/14
IMM Prima Newsletter31/07/14
IMM Appendix 4C - quarterlyPRICE SENSITIVE31/07/14
IMM CEO Terms of Employment22/07/14
IMM Prima receives US patent grant for CVacPRICE SENSITIVE16/07/14
IMM Initial Director's Interest Notice15/07/14
IMM Final Director's Interest Notice15/07/14
IMM Prima appoints new CEOPRICE SENSITIVE09/07/14
IMM Journal for Immunotherapy of Cancer Publication23/06/14
IMM Prima to present at 2014 WAGO Annual Meeting19/06/14
IMMTranscript of CAN-003 data conference call04/06/14
IMMSupplemental information for CAN-003 data conference call02/06/14
IMMQ&A with Dr Gray on CAN-003 data presented at ASCO02/06/14
IMMCVac demonstrates positive trend in Overall SurvivalPRICE SENSITIVE02/06/14
IMMConference call to discuss CAN-003 data presented at ASCO30/05/14
IMMUSA Patent for CVac AllowedPRICE SENSITIVE26/05/14
IMMCVac demonstrates clinically meaningful improvement in PFSPRICE SENSITIVE15/05/14
IMMPrima BioMed's CVac granted Fast Track Designation by FDAPRICE SENSITIVE09/05/14
IMMSupplemental Information for Quarterly Conference CallPRICE SENSITIVE06/05/14
IMMPrima Newsletter05/05/14
IMMThird Quarter Conference Call29/04/14
IMMAppendix 4C - quarterlyPRICE SENSITIVE29/04/14
IMMPrima commences recruitment for CAN 004 Phase 2 trialPRICE SENSITIVE28/04/14
IMMPrima to present at Needham Healthcare Conference07/04/14
IMMCVac Improvement in 2nd Remission Data Accepted for ASCOPRICE SENSITIVE28/03/14
IMMNew Appointments to Clinical Advisory Board25/03/14
AAI +S&P DJ Indices Announces March Quarterly Rebalance07/03/14
IMM$1.6 million R&D Tax Incentive Refund ReceivedPRICE SENSITIVE05/03/14
IMMPrima to present at Regen Med Investor Day27/02/14
IMMPrima to present at Wall Street Analyst Forum27/02/14
IMMPrima and Neopharm execute final CVac licensing agreementPRICE SENSITIVE21/02/14
IMMDr Monk to Join Prima BioMed Clinical Advisory Board20/02/14
IMMHalf Yearly Report and AccountsPRICE SENSITIVE18/02/14
IMMAppendix 3X13/02/14
IMMAppendix 3Z13/02/14
IMMAppointment & Retirement of Non-Executive Director12/02/14
IMMSupplemental Information for Quarterly Conference Call06/02/14
IMMCAN-004 Amendment Approved in Multiple JurisdictionsPRICE SENSITIVE06/02/14
IMMPrima to present at Annual BIO CEO & Investor Conference31/01/14
IMMSecond Quarter Highlights and Conference Call29/01/14
IMMAppendix 4C - quarterlyPRICE SENSITIVE29/01/14
IMMAppendix 3B24/01/14
IMMPrima CEO to be interviewed on live US Radio Show09/01/14
IMMAppendix 3B27/12/13
IMMPrima Analyst Briefing Document09/12/13
IMMPoster for Society for Immunotherapy of Cancer Meeting26/11/13
IMMPresentation slides for Regenerative Medicine Meeting26/11/13
IMMExpert panel to discuss CVac clinical trial data26/11/13
IMMAppendix 3Z22/11/13
IMMChange of Director's Interest Notice21/11/13
IMMPrima presents at Regenerative Medicine Meeting20/11/13
IMMChange of Director's Interest Notice19/11/13
IMMResults of Meeting15/11/13
IMM2013 AGM Chairman Address15/11/13
IMM2013 AGM CEO presentation slides15/11/13
IMM Information Required Under Listing Rule 3.10.5A
15/05/15
IMM Appendix 3B
15/05/15
IMM Prima Biomed Announces A$15m Investment from Ridgeback
14/05/15PRICE SENSITIVE
IMM Prima announces Japanese Collaboration
11/05/15PRICE SENSITIVE
IMM Prima to present at Canary Networks Investor Roadshow
29/04/15
IMM Appendix 4C - quarterly
16/04/15PRICE SENSITIVE
IMM Half Yearly Report and Accounts
27/02/15PRICE SENSITIVE
IMM Prima BioMed Prioritising IMP 321
27/02/15PRICE SENSITIVE
IMM Detailed Investor Presentation
27/02/15
IMM Introductory Investor Presentation
27/02/15
IMM Appendix 4C - quarterly
30/01/15PRICE SENSITIVE
IMM Financial milestone payment to be received from GSK
27/01/15PRICE SENSITIVE
IMM Cleansing Notice & Appendix 3B
23/01/15
IMM R&D Tax Incentive Refund Received
20/01/15PRICE SENSITIVE
IMM Stuart Roberts appointed Global Head of Investor Relations
20/01/15
IMM Change of Director's Interest Notice
07/01/15
IMM Prima receives NASDAQ deficiency notice
29/12/14
IMM Notice of Grant received from Canadian Patent Office
22/12/14PRICE SENSITIVE
IMM Prima completes acquisition of Immutep
17/12/14PRICE SENSITIVE
IMM Prima initiates Pancreatic Clinical Trial with CVac
15/12/14PRICE SENSITIVE
IMM Appendix 3B
12/12/14
IMM Cleansing Notice & Appendix 3B
12/12/14
IMM Cleansing Notice & Appendix 3B
11/12/14
IMM Enhancement of manufacturing and logistics capabilities
05/12/14PRICE SENSITIVE
IMM Change of Director's Interest Notice
28/11/14
IMM Appendix 3B
28/11/14
IMM Results of Meeting
14/11/14
IMM 2014 AGM Presentations
14/11/14
IMM 2014 AGM Chairman's Address
14/11/14
IMM Society for Immunotherapy of Cancer poster presentation
10/11/14
IMM Cleansing Notice & Appendix 3B
06/11/14
IMM CVac demonstrates overall survival benefit
06/11/14PRICE SENSITIVE
IMM Supplemental Information for Shareholder Conference Call
23/10/14
IMM Conference Call to discuss acquisition of Immutep
21/10/14
IMM Appendix 4C - quarterly
21/10/14PRICE SENSITIVE
IMM Notice of Allowance for IMP321 Patent
14/10/14PRICE SENSITIVE
IMM Prima Newsletter
13/10/14
IMM Notice of Annual General Meeting/Proxy Form
13/10/14
IMM Annual Report to Shareholders
10/10/14
IMM Annual Report on Form 20-F filed with SEC
10/10/14
IMM Cleansing Notice & Appendix 3B
02/10/14
IMM Prima secures funding from US institutional investor
02/10/14
IMM Proposed Acquisition of Immutep
02/10/14PRICE SENSITIVE
IMM Appendix 3B
19/09/14
IMM Appendix 4E & 2014 Full Year Statutory Accounts
27/08/14PRICE SENSITIVE
IMM Prima to present at Society for Immunotherapy of Cancer
19/08/14
IMM Prima Newsletter
31/07/14
IMM Appendix 4C - quarterly
31/07/14PRICE SENSITIVE
IMM CEO Terms of Employment
22/07/14
IMM Prima receives US patent grant for CVac
16/07/14PRICE SENSITIVE
IMM Initial Director's Interest Notice
15/07/14
IMM Final Director's Interest Notice
15/07/14
IMM Prima appoints new CEO
09/07/14PRICE SENSITIVE
IMM Journal for Immunotherapy of Cancer Publication
23/06/14
IMM Prima to present at 2014 WAGO Annual Meeting
19/06/14
IMMTranscript of CAN-003 data conference call
04/06/14
IMMSupplemental information for CAN-003 data conference call
02/06/14
IMMQ&A with Dr Gray on CAN-003 data presented at ASCO
02/06/14
IMMCVac demonstrates positive trend in Overall Survival
02/06/14PRICE SENSITIVE
IMMConference call to discuss CAN-003 data presented at ASCO
30/05/14
IMMUSA Patent for CVac Allowed
26/05/14PRICE SENSITIVE
IMMCVac demonstrates clinically meaningful improvement in PFS
15/05/14PRICE SENSITIVE
IMMPrima BioMed's CVac granted Fast Track Designation by FDA
09/05/14PRICE SENSITIVE
IMMSupplemental Information for Quarterly Conference Call
06/05/14PRICE SENSITIVE
IMMPrima Newsletter
05/05/14
IMMThird Quarter Conference Call
29/04/14
IMMAppendix 4C - quarterly
29/04/14PRICE SENSITIVE
IMMPrima commences recruitment for CAN 004 Phase 2 trial
28/04/14PRICE SENSITIVE
IMMPrima to present at Needham Healthcare Conference
07/04/14
IMMCVac Improvement in 2nd Remission Data Accepted for ASCO
28/03/14PRICE SENSITIVE
IMMNew Appointments to Clinical Advisory Board
25/03/14
AAI +S&P DJ Indices Announces March Quarterly Rebalance
07/03/14
IMM$1.6 million R&D Tax Incentive Refund Received
05/03/14PRICE SENSITIVE
IMMPrima to present at Regen Med Investor Day
27/02/14
IMMPrima to present at Wall Street Analyst Forum
27/02/14
IMMPrima and Neopharm execute final CVac licensing agreement
21/02/14PRICE SENSITIVE
IMMDr Monk to Join Prima BioMed Clinical Advisory Board
20/02/14
IMMHalf Yearly Report and Accounts
18/02/14PRICE SENSITIVE
IMMAppendix 3X
13/02/14
IMMAppendix 3Z
13/02/14
IMMAppointment & Retirement of Non-Executive Director
12/02/14
IMMSupplemental Information for Quarterly Conference Call
06/02/14
IMMCAN-004 Amendment Approved in Multiple Jurisdictions
06/02/14PRICE SENSITIVE
IMMPrima to present at Annual BIO CEO & Investor Conference
31/01/14
IMMSecond Quarter Highlights and Conference Call
29/01/14
IMMAppendix 4C - quarterly
29/01/14PRICE SENSITIVE
IMMAppendix 3B
24/01/14
IMMPrima CEO to be interviewed on live US Radio Show
09/01/14
IMMAppendix 3B
27/12/13
IMMPrima Analyst Briefing Document
09/12/13
IMMPoster for Society for Immunotherapy of Cancer Meeting
26/11/13
IMMPresentation slides for Regenerative Medicine Meeting
26/11/13
IMMExpert panel to discuss CVac clinical trial data
26/11/13
IMMAppendix 3Z
22/11/13
IMMChange of Director's Interest Notice
21/11/13
IMMPrima presents at Regenerative Medicine Meeting
20/11/13
IMMChange of Director's Interest Notice
19/11/13
IMMResults of Meeting
15/11/13
IMM2013 AGM Chairman Address
15/11/13
IMM2013 AGM CEO presentation slides
15/11/13
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
28.5¢ 		Change
-0.020(6.56%) 		Mkt cap ! $486.6M
Open High Low Value Volume
30.5¢ 30.5¢ 28.5¢ $913.3K 3.099M

Buyers (Bids)

No. Vol. Price($)
6 124895 28.5¢
 

Sellers (Offers)

Price($) Vol. No.
29.0¢ 30287 2
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
28.5¢ 		  Change
-0.020 ( 6.80 %)
Open High Low Volume
30.5¢ 30.5¢ 28.5¢ 1420446
Last updated 15.59pm 21/11/2024 ?
IMM (ASX) Chart

Top Stories

Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech

Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.